{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:36:18Z","timestamp":1789706178430,"version":"4.0.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-71019-5","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T10:15:40Z","timestamp":1774952140000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Concurrent chemoradiotherapy plus nimotuzumab versus chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma with a suboptimal response to induction chemotherapy: a randomized phase 2 trial"],"prefix":"10.1038","volume":"17","author":[{"given":"Li-Ting","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Song","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Ting","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Yuan","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-Shan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai-Lan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Hua","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Dong","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7632-3648","authenticated-orcid":false,"given":"Ji-Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Jing","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Fu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Xiong","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Hao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0916-5704","authenticated-orcid":false,"given":"Qi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Xiang","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Jie","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3271-5783","authenticated-orcid":false,"given":"Chong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7305-5051","authenticated-orcid":false,"given":"Qiu-Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9613-7305","authenticated-orcid":false,"given":"Lin-Quan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9035-6814","authenticated-orcid":false,"given":"Hai-Qiang","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"71019_CR1","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa1905287","volume":"381","author":"Y Zhang","year":"2019","unstructured":"Zhang, Y. et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N. Engl. J. Med. 381, 1124\u20131135 (2019).","journal-title":"N. Engl. J. Med."},{"key":"71019_CR2","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","volume":"17","author":"Y Sun","year":"2016","unstructured":"Sun, Y. et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 17, 1509\u20131520 (2016).","journal-title":"Lancet Oncol."},{"key":"71019_CR3","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1200\/JCO.20.03237","volume":"39","author":"YP Chen","year":"2021","unstructured":"Chen, Y. P. et al. Chemotherapy in combination with radiotherapy for definitive-intent treatment of Stage II-IVA nasopharyngeal carcinoma: CSCO and ASCO Guideline. J. Clin. Oncol. 39, 840\u2013859 (2021).","journal-title":"J. Clin. Oncol."},{"key":"71019_CR4","unstructured":"NCCN. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Head and Neck Cancers (Version 1.2025). Available at: https:\/\/www.nccn.org (accessed January 2025) (2025)."},{"key":"71019_CR5","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.ijrobp.2015.08.003","volume":"93","author":"LT Liu","year":"2015","unstructured":"Liu, L. T. et al. The prognostic value of plasma Epstein-Barr Viral DNA and tumor response to neoadjuvant chemotherapy in advanced-stage nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 93, 862\u2013869 (2015).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"71019_CR6","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ijrobp.2019.01.007","volume":"104","author":"CL Huang","year":"2019","unstructured":"Huang, C. L. et al. Plasma Epstein-Barr Virus DNA load after induction chemotherapy predicts outcome in locoregionally advanced nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 104, 355\u2013361 (2019).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"71019_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11853-y","volume":"10","author":"J Lv","year":"2019","unstructured":"Lv, J. et al. Liquid biopsy tracking during sequential chemo-radiotherapy identifies distinct prognostic phenotypes in nasopharyngeal carcinoma. Nat. Commun. 10, 3941 (2019).","journal-title":"Nat. Commun."},{"key":"71019_CR8","first-page":"2958","volume":"7","author":"F Ciardiello","year":"2001","unstructured":"Ciardiello, F. & Tortora, G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res. 7, 2958\u20132970 (2001).","journal-title":"Clin. Cancer Res."},{"key":"71019_CR9","doi-asserted-by":"crossref","first-page":"1s","DOI":"10.1200\/JCO.2002.20.1.1","volume":"20","author":"J Mendelsohn","year":"2002","unstructured":"Mendelsohn, J. Targeting the epidermal growth factor receptor for cancer therapy. J. Clin. Oncol. 20, 1s\u201313s (2002).","journal-title":"J. Clin. Oncol."},{"key":"71019_CR10","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","volume":"359","author":"JB Vermorken","year":"2008","unstructured":"Vermorken, J. B. et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 359, 1116\u20131127 (2008).","journal-title":"N. Engl. J. Med."},{"key":"71019_CR11","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/S1470-2045(20)30755-5","volume":"22","author":"J Guigay","year":"2021","unstructured":"Guigay, J. et al. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 22, 463\u2013475 (2021).","journal-title":"Lancet Oncol."},{"key":"71019_CR12","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.3389\/fonc.2020.01011","volume":"10","author":"M Zhang","year":"2020","unstructured":"Zhang, M. et al. Long-term survival of patients with chemotherapy-na\u00efve metastatic nasopharyngeal carcinoma receiving cetuximab plus docetaxel and cisplatin regimen. Front. Oncol. 10, 1011 (2020).","journal-title":"Front. Oncol."},{"key":"71019_CR13","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMoa053422","volume":"354","author":"JA Bonner","year":"2006","unstructured":"Bonner, J. A. et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354, 567\u2013578 (2006).","journal-title":"N. Engl. J. Med."},{"key":"71019_CR14","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","volume":"393","author":"ML Gillison","year":"2019","unstructured":"Gillison, M. L. et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet 393, 40\u201350 (2019).","journal-title":"Lancet"},{"key":"71019_CR15","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1200\/JCO.2013.53.5633","volume":"32","author":"KK Ang","year":"2014","unstructured":"Ang, K. K. et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J. Clin. Oncol. 32, 2940\u20132950 (2014).","journal-title":"J. Clin. Oncol."},{"key":"71019_CR16","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S1470-2045(14)71198-2","volume":"16","author":"R Mes\u00eda","year":"2015","unstructured":"Mes\u00eda, R. et al. Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial. Lancet Oncol. 16, 208\u2013220 (2015).","journal-title":"Lancet Oncol."},{"key":"71019_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ijrobp.2003.10.038","volume":"59","author":"DT Chua","year":"2004","unstructured":"Chua, D. T., Nicholls, J. M., Sham, J. S. & Au, G. K. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 59, 11\u201320 (2004).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"71019_CR18","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1093\/annonc\/mdr401","volume":"23","author":"BBY Ma","year":"2012","unstructured":"Ma, B. B. Y. et al. A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma. Ann. Oncol. 23, 1287\u20131292 (2012).","journal-title":"Ann. Oncol."},{"key":"71019_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4161\/mabs.1.1.7509","volume":"1","author":"MS Ramakrishnan","year":"2009","unstructured":"Ramakrishnan, M. S. et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. mAbs 1, 41\u201348 (2009).","journal-title":"mAbs"},{"key":"71019_CR20","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1089\/hyb.2007.0516","volume":"26","author":"A Diaz Miqueli","year":"2007","unstructured":"Diaz Miqueli, A. et al. Biological activity in vitro of anti-epidermal growth factor receptor monoclonal antibodies with different affinities. Hybridoma 26, 423\u2013431 (2007).","journal-title":"Hybridoma"},{"key":"71019_CR21","doi-asserted-by":"publisher","first-page":"3184","DOI":"10.1002\/cncr.32179","volume":"125","author":"VM Patil","year":"2019","unstructured":"Patil, V. M. et al. A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer. Cancer 125, 3184\u20133197 (2019).","journal-title":"Cancer"},{"key":"71019_CR22","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1093\/annonc\/mdz020","volume":"30","author":"C Zhao","year":"2019","unstructured":"Zhao, C. et al. Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with cisplatin and 5-fluorouracil in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: a multicentre, open-label, phase II clinical trial. Ann. Oncol. 30, 637\u2013643 (2019).","journal-title":"Ann. Oncol."},{"key":"71019_CR23","doi-asserted-by":"publisher","first-page":"24429","DOI":"10.18632\/oncotarget.8225","volume":"7","author":"ZG Liu","year":"2016","unstructured":"Liu, Z. G. et al. Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a retrospective analysis. Oncotarget 7, 24429\u201324435 (2016).","journal-title":"Oncotarget"},{"key":"71019_CR24","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3727\/096504017X15079846743590","volume":"26","author":"W Fangzheng","year":"2018","unstructured":"Fangzheng, W. et al. Long-term use of nimotuzumab in combination with intensity-modulated radiotherapy and chemotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma: experience of a single institution. Oncol. Res. 26, 277\u2013287 (2018).","journal-title":"Oncol. Res."},{"key":"71019_CR25","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1080\/15384047.2018.1491501","volume":"19","author":"JJ Yao","year":"2018","unstructured":"Yao, J. J. et al. Comparing treatment outcomes of concurrent chemoradiotherapy with or without nimotuzumab in patients with locoregionally advanced nasopharyngeal carcinoma. Cancer Biol. Ther. 19, 1102\u20131107 (2018).","journal-title":"Cancer Biol. Ther."},{"key":"71019_CR26","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1007\/s00432-022-04355-w","volume":"149","author":"Z Cai","year":"2023","unstructured":"Cai, Z. et al. Concurrent chemoradiotherapy combined with nimotuzumab in stage III-IVa nasopharyngeal carcinoma: a retrospective analysis. J. Cancer Res. Clin. Oncol. 149, 2327\u20132344 (2023).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"71019_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1366853","volume":"15","author":"RJ Wang","year":"2024","unstructured":"Wang, R. J., Ke, R. Q., Yu, Y. F., Lu, G. Z. & Wu, S. G. Addition of nimotuzumab to concurrent chemoradiotherapy after induction chemotherapy improves outcomes of patients with locally advanced nasopharyngeal carcinoma. Front. Pharmacol. 15, 1366853 (2024).","journal-title":"Front. Pharmacol."},{"key":"71019_CR28","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.18632\/oncotarget.13899","volume":"8","author":"JF Huang","year":"2017","unstructured":"Huang, J. F. et al. Induction chemotherapy followed by concurrent chemoradiation and nimotuzumab for locoregionally advanced nasopharyngeal carcinoma: preliminary results from a phase II clinical trial. Oncotarget 8, 2457\u20132465 (2017).","journal-title":"Oncotarget"},{"key":"71019_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101797","volume":"39","author":"X Niu","year":"2024","unstructured":"Niu, X. et al. Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with chemoradiotherapy for induction chemotherapy resistant locally advanced nasopharyngeal carcinoma: a prospective phase II study. Transl. Oncol. 39, 101797 (2024).","journal-title":"Transl. Oncol."},{"key":"71019_CR30","doi-asserted-by":"publisher","first-page":"224","DOI":"10.6004\/jnccn.2022.0016","volume":"20","author":"JJ Caudell","year":"2022","unstructured":"Caudell, J. J. et al. NCCN Guidelines\u00ae Insights: Head and Neck Cancers, Version 1.2022. J. Natl. Compr. Cancer Netw. 20, 224\u2013234 (2022).","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"71019_CR31","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1200\/JCO.22.00327","volume":"40","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. Final overall survival analysis of gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma: a multicenter, randomized phase III trial. J. Clin. Oncol. 40, 2420\u20132425 (2022).","journal-title":"J. Clin. Oncol."},{"key":"71019_CR32","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S1470-2045(23)00163-8","volume":"24","author":"C Petit","year":"2023","unstructured":"Petit, C. et al. Role of chemotherapy in patients with nasopharynx carcinoma treated with radiotherapy (MAC-NPC): an updated individual patient data network meta-analysis. Lancet Oncol. 24, 611\u2013623 (2023).","journal-title":"Lancet Oncol."},{"key":"71019_CR33","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.oraloncology.2016.10.014","volume":"62","author":"H Peng","year":"2016","unstructured":"Peng, H. et al. Optimize the cycle of neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: a propensity score matching analysis. Oral Oncol. 62, 78\u201384 (2016).","journal-title":"Oral Oncol."},{"key":"71019_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113336","volume":"194","author":"SS Guo","year":"2023","unstructured":"Guo, S. S. et al. Reduced-dose radiotherapy for Epstein-Barr virus DNA selected staged III nasopharyngeal carcinoma: a single-arm, phase 2 trial. Eur. J. Cancer 194, 113336 (2023).","journal-title":"Eur. J. Cancer"},{"key":"71019_CR35","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1200\/JCO.2008.18.1545","volume":"27","author":"EP Hui","year":"2009","unstructured":"Hui, E. P. et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J. Clin. Oncol. 27, 242\u2013249 (2009).","journal-title":"J. Clin. Oncol."},{"key":"71019_CR36","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.radonc.2021.08.010","volume":"163","author":"T Liu","year":"2021","unstructured":"Liu, T. et al. Management of suboptimal response to induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Re-induction therapy or direct to Radiotherapy? Radiother. Oncol. 163, 185\u2013191 (2021).","journal-title":"Radiother. Oncol."},{"key":"71019_CR37","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.ccell.2024.07.001","volume":"42","author":"J Lv","year":"2024","unstructured":"Lv, J. et al. Longitudinal on-treatment circulating tumor DNA as a biomarker for real-time dynamic risk monitoring in cancer patients: the EP-SEASON study. Cancer Cell 42, 1401\u20131414.e1404 (2024).","journal-title":"Cancer Cell"},{"key":"71019_CR38","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1001\/jamaoncol.2025.1597","volume":"11","author":"SS Guo","year":"2025","unstructured":"Guo, S. S. et al. Induction vs adjuvant chemoradiotherapy in patients with high-risk N2 to N3 nasopharyngeal carcinoma: a phase 3 randomized clinical trial. JAMA Oncol. 11, 864\u2013873 (2025).","journal-title":"JAMA Oncol."},{"key":"71019_CR39","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/d41586-022-01866-x","volume":"608","author":"SK Rehman","year":"2022","unstructured":"Rehman, S. K. & O\u2019Brien, C. A. Persister cells that survive chemotherapy are pinpointed. Nature 608, 675\u2013676 (2022).","journal-title":"Nature"},{"key":"71019_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2021.105506","volume":"122","author":"X Zhou","year":"2021","unstructured":"Zhou, X. et al. Survival impact of increasing time to IMRT initiation following induction chemotherapy in nasopharyngeal carcinoma: a propensity score-matched analysis. Oral. Oncol. 122, 105506 (2021).","journal-title":"Oral. Oncol."},{"key":"71019_CR41","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1288\/00005537-199404000-00012","volume":"104","author":"J Bourhis","year":"1994","unstructured":"Bourhis, J. et al. Rapid tumor cell proliferation after induction chemotherapy in oropharyngeal cancer. Laryngoscope 104, 468\u2013472 (1994).","journal-title":"Laryngoscope"},{"key":"71019_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110649","volume":"131","author":"X Chen","year":"2020","unstructured":"Chen, X., Liang, R. & Zhu, X. Anti-EGFR therapies in nasopharyngeal carcinoma. Biomed. Pharmacother. 131, 110649 (2020).","journal-title":"Biomed. Pharmacother."},{"key":"71019_CR43","first-page":"4637","volume":"53","author":"Z Fan","year":"1993","unstructured":"Fan, Z., Baselga, J., Masui, H. & Mendelsohn, J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res. 53, 4637\u20134642 (1993).","journal-title":"Cancer Res."},{"key":"71019_CR44","first-page":"1935","volume":"59","author":"SM Huang","year":"1999","unstructured":"Huang, S. M., Bock, J. M. & Harari, P. M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 59, 1935\u20131940 (1999).","journal-title":"Cancer Res."},{"key":"71019_CR45","first-page":"909","volume":"5","author":"F Ciardiello","year":"1999","unstructured":"Ciardiello, F. et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin. Cancer Res. 5, 909\u2013916 (1999).","journal-title":"Clin. Cancer Res."},{"key":"71019_CR46","first-page":"4874","volume":"6","author":"K Inoue","year":"2000","unstructured":"Inoue, K. et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin. Cancer Res. 6, 4874\u20134884 (2000).","journal-title":"Clin. Cancer Res."},{"key":"71019_CR47","first-page":"994","volume":"8","author":"MC Prewett","year":"2002","unstructured":"Prewett, M. C. et al. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin. Cancer Res. 8, 994\u20131003 (2002).","journal-title":"Clin. Cancer Res."},{"key":"71019_CR48","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.1200\/JCO.2005.02.147","volume":"23","author":"AT Chan","year":"2005","unstructured":"Chan, A. T. et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J. Clin. Oncol. 23, 3568\u20133576 (2005).","journal-title":"J. Clin. Oncol."},{"key":"71019_CR49","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1200\/JCO.2012.46.0816","volume":"31","author":"LQ Tang","year":"2013","unstructured":"Tang, L. Q. et al. Prospective study of tailoring whole-body dual-modality [18F]fluorodeoxyglucose positron emission tomography\/computed tomography with plasma Epstein-Barr virus DNA for detecting distant metastasis in endemic nasopharyngeal carcinoma at initial staging. J. Clin. Oncol. 31, 2861\u20132869 (2013).","journal-title":"J. Clin. Oncol."},{"key":"71019_CR50","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1002\/cncr.20099","volume":"100","author":"JY Shao","year":"2004","unstructured":"Shao, J. Y. et al. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A\/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma. Cancer 100, 1162\u20131170 (2004).","journal-title":"Cancer"},{"key":"71019_CR51","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1002\/cncr.25932","volume":"117","author":"X An","year":"2011","unstructured":"An, X. et al. Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic\/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy. Cancer 117, 3750\u20133757 (2011).","journal-title":"Cancer"},{"key":"71019_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-5192-x","volume":"18","author":"SL Liu","year":"2018","unstructured":"Liu, S. L. et al. Liposomal paclitaxel versus docetaxel in induction chemotherapy using Taxanes, cisplatin and 5-fluorouracil for locally advanced nasopharyngeal carcinoma. BMC Cancer 18, 1279 (2018).","journal-title":"BMC Cancer"},{"key":"71019_CR53","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1080\/14656566.2016.1204293","volume":"17","author":"Y Wang","year":"2016","unstructured":"Wang, Y. et al. A triplet chemotherapy regimen of cisplatin, fluorouracil and paclitaxel for locoregionally recurrent nasopharyngeal carcinoma cases contraindicated for re-irradiation\/surgery. Expert Opin. Pharmacother. 17, 1585\u20131590 (2016).","journal-title":"Expert Opin. Pharmacother."},{"key":"71019_CR54","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.ijrobp.2010.03.024","volume":"80","author":"SZ Lai","year":"2011","unstructured":"Lai, S. Z. et al. How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? Int. J. Radiat. Oncol. Biol. Phys. 80, 661\u2013668 (2011).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"71019_CR55","doi-asserted-by":"crossref","unstructured":"Zhang, Q., Huang, S. & Lin, S. Delineation of clinical target volume in nasopharyngeal carcinoma. Holist. Integr. Oncol. 2, 22 (2023).","DOI":"10.1007\/s44178-023-00045-w"},{"key":"71019_CR56","doi-asserted-by":"publisher","first-page":"7199","DOI":"10.1200\/JCO.2005.01.149","volume":"23","author":"LV Rubinstein","year":"2005","unstructured":"Rubinstein, L. V. et al. Design issues of randomized phase II trials and a proposal for phase II screening trials. J. Clin. Oncol. 23, 7199\u20137206 (2005).","journal-title":"J. Clin. Oncol."},{"key":"71019_CR57","doi-asserted-by":"crossref","unstructured":"Schoenfeld, D. Partial residuals for the proportional hazards regression model. Biometrika 69, 239\u2013241 (1982).","DOI":"10.1093\/biomet\/69.1.239"},{"key":"71019_CR58","doi-asserted-by":"crossref","unstructured":"Fine J. P. & Gray R. J. A proportional hazards model for the subdistribution of a competing risk. J. Am. Stat. Assoc. 94, 496\u2013509 (1999).","DOI":"10.1080\/01621459.1999.10474144"},{"key":"71019_CR59","doi-asserted-by":"publisher","unstructured":"Rytgaard, H. C. W., Eriksson, F. & van der Laan, M. J. Estimation of time-specific intervention effects on continuously distributed time-to-event outcomes by targeted maximum likelihood estimation. Biometrics https:\/\/doi.org\/10.1111\/biom.13856 (2023).","DOI":"10.1111\/biom.13856"},{"key":"71019_CR60","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.jclinepi.2010.11.016","volume":"64","author":"DJ Fisher","year":"2011","unstructured":"Fisher, D. J., Copas, A. J., Tierney, J. F. & Parmar, M. K. A critical review of methods for the assessment of patient-level interactions in individual participant data meta-analysis of randomized trials, and guidance for practitioners. J. Clin. Epidemiol. 64, 949\u2013967 (2011).","journal-title":"J. Clin. Epidemiol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71019-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71019-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71019-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T01:02:20Z","timestamp":1779670940000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71019-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["71019"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-71019-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"15 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4631"}}